Based on evidence that arsenic modulates proinflammatory events that are involved in skin carcinogenecity, we hypothesized that in normal human epidermal keratinocytes (NHEK) arsenic increases expression of the procarcinogenic enzyme cyclooxygenase-2 (COX-2) and that this occurs via specific mitogen and stress signaling pathways. To test this hypothesis, NHEK were exposed to sodium arsenite, and COX-2 expression, prostaglandin E2 (PGE 2 ) secretion, mitogen-activated protein kinase (MAPK) phosphorylation, and DNA synthesis were quantified. Inhibitors of p42/44 and p38 MAPKs were used to evaluate the contribution of mitogen and stress signaling to the modulation of COX-2. Our results demonstrate that arsenite (0.005-5 M) elevates COX-2 expression, PGE 2 secretion (2.5-5 M), and DNA synthesis (1-5 M). Arsenite stimulated p42/44 but not p38 MAPK phosphorylation (2.5 M), responses different than those produced by epidermal growth factor. Inhibition of mitogen-activated protein kinase kinase (MAPKK) and p38 MAPK using PD98059 (20 M) and SB202190 (5 M), respectively, attenuated the elevation of COX-2 protein induced by arsenite, whereas physiological concentrations of three COX-2 inhibitors (e.g., NS-398, piroxicam, and aspirin) reduced arsenite-stimulated DNA synthesis. These data indicate that arsenite elevates COX-2 in NHEK at the transcriptional and translational levels as well as increases PGE 2 secretion. Compounds that inhibit COX-2 expression and activity may be useful in the scientific study, prevention, and treatment of arsenic skin carcinogenesis and deserve further investigation.
Exposure of human populations to environmental arsenic is associated with skin cancer and various internal cancers, including bladder, kidney, liver, and lung cancer (Rossman, 2003) . Skin cancer and precancerous skin lesions linked with arsenic exposure pose a serious problem to human health, particularly in Bangladesh and India where millions of people are exposed to high levels of arsenic in drinking water (Chowdhury et al., 2000) . In the United States, 11 states have been identified with arsenic concentrations in drinking water above the Environmental Protection Agency's current maximum contaminant level (MCL) for arsenic, and it is estimated that more than 34 million Americans are at risk for developing disease from the consumption of arsenic-contaminated drinking water (Frost et al., 2003) . Because humans are exposed to arsenic through both natural and anthropogenic contamination, elucidating its carcinogenic mechanism of action and determining concentrations that promote precancerous or toxic events are essential.
Arsenic exposure through drinking water is normally in the form of either arsenite (trivalent) or arsenate (pentavalent), and the increased cancer risk, particularly for skin cancer, is attributed primarily to the presence of inorganic trivalent arsenic (Rossman, 2003) . This is supported by evidence that sulfhydryl groups, which have a high affinity for trivalent arsenic, are abundant in keratin (Leonard and Lauwerys, 1980) , and the production of organic arsenic metabolites that have demonstrated carcinogenecity (Hughes, 2002) does not occur in human keratinocytes in vitro (Styblo et al., 1999) . Inorganic trivalent arsenic also modulates epidermal gene and protein expression (Germolec et al., 1996; Hamadeh et al., 2002) and behaves similar to tumor-promoting agents via its ability to modulate proliferation and mitogenic signaling (Simeonova and Luster, 2000; Trouba et al., 2000) . However, unlike most tumor promoters, inorganic trivalent arsenic is a known carcinogen in humans. Although the mechanisms contributing to arsenic carcinogenesis are proposed to include genotoxicity, DNA methylation perturbations, oxidative stress, abnormal cell proliferation, cocarcinogenesis, and tumor promotion (Hughes, 2002) , proinflammatory mediators associated with arsenic skin carcinogenesis are hypothesized to contribute significantly to 1 To whom correspondence should be addressed at Environmental Immunology, National Institute of Environmental Health Sciences, National the tumor promoter-like activity of this metalloid (Germolec et al., 1996; Vega et al., 2001) .
Expression of cyclooxygenase-2 (COX-2), an inducible proinflammatory enzyme that regulates eicosanoid synthesis, often is elevated during cancer and is induced by tumor promoters, inflammatory cytokines, and growth factors (Fosslien, 2000) . COX-2 is procarcinogenic as demonstrated by experiments where tumorigenesis was inhibited in COX-2 knockout mice and cancer chemoprevention studies that employed nonsteroidal anti-inflammatory drugs (NSAIDs; Vainio, 2001) . Elevated eicosanoid (e.g., prostaglandin E2 [PGE 2 ]) levels also occur in both basal and squamous cell carcinomas of the skin (Vanderveen et al., 1986) and are associated with increased metastatic and invasive tumor behavior (Cuendet and Pezzuto, 2000) . Because COX-2 is proinflammatory and its overexpression sensitizes mouse skin for carcinogenesis (Muller-Decker et al., 2002) , the mechanism(s) by which inorganic trivalent arsenic modulates inflammatory and proliferative events in the skin may involve aberrant COX-2 expression and activity.
Mitogen-activated protein kinase (MAPK) pathways regulate cell growth, transformation, apoptosis, and inflammation and modulate COX-2 expression and activity. The MAPK family includes c-Jun NH 2 -terminal kinases (JNKs), extracellular signal-regulated kinases (ERKs or p42/44 MAPK), and p38 MAPK/stress-activated protein kinases (SAPKs). MAPKs phosphorylate transcription factors (e.g., Elk-1) regulating cox-2 expression (Lasa et al., 2000) and accessory proteins (e.g., cPLA2) that play an active role in eicosanoid synthesis (Schmidlin et al., 2000) . Arsenic stimulates MAPK signaling events (Barchowsky et al., 1999; Drobna et al., 2003; Qu et al., 2002; Simeonova et al., 2002) , possibly contributing to alterations in COX-2 expression/activity (Tsai et al., 2002) . However, simultaneous COX-2 modulation and MAPK activation by inorganic trivalent arsenic has not been demonstrated in epithelial cells, particularly in human keratinocytes, one of the primary targets for the induction of cancer by arsenic.
Because elevated COX-2 expression occurs in skin inflammation and cancer and keratinocytes are the primary site of COX-2 synthesis during these processes, we examined if sodium arsenite modulates COX-2 expression and PGE 2 secretion in NHEK and the possible signaling mechanism(s) by which arsenite regulates COX-2 in keratinocytes.
MATERIALS AND METHODS
Reagents. Keratinocyte basal medium (KBM-2) and growth supplements were obtained from BioWhittaker/Clonetics (Walkersville, MD), and Trypsin-EDTA, Soybean Trypsin Inhibitor, and recombinant human epidermal growth factor (EGF) were obtained from Invitrogen (Carlsbad, CA). Sodium-marsenite, N-(2-cyclohexyloxy-4-nitrophenyl) methanesulfonamide (NS-398), and acetylsalicylic acid (aspirin) were obtained from Sigma Chemical Co. (St. Louis, MO), and PD98059, SB202190, and 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamid-1,1-dioxid (piroxicam) were obtained from Calbiochem (San Diego, CA). Arsenite stocks were prepared in deionized water, frozen at -80°C, and used within 2 weeks. MAPK inhibitors and NS-398 were dissolved in dimethylsulfoxide (DMSO) and frozen at -80°C prior to use. Aspirin and piroxicam were prepared freshly in ethanol and DMSO, respectively.
Tissue culture. Normal human mammary epidermal keratinocytes (NHEK), obtained from BioWhittaker/Clonetics, were cultured in monolayer at passage Յ 6 in low calcium concentration (0.15 mM) growth medium (KBM-2) supplemented with EGF (5 ng/ml), bovine pituitary extract (BPE, 50 mg/ml), 0.5 mg/ml hydrocortisone, 50 g gentamicin/ml, transferrin, and epinephrine. Cells were incubated at 37°C in a CO 2 -enriched atmosphere (5%). For all experiments, cells were cultured to 60 -80% confluence (2 to 3 days postplating). Subsequent treatment of cells with noncytotoxic concentrations of sodium arsenite (Hamadeh et al., 2002) was performed in supplemented KBM-2 minus BPE and hydrocortisone (KBM-2 ) to eliminate the mitogenic effects of BPE and anti-inflammatory effects of hydrocortisone. EGF present in KBM-2 did not interfere with MAPK activation by arsenite (unpublished data). PD98059, SB202190, or vehicle (DMSO) treatment was performed at the time of medium replacement (KBM-2 ), 1 to 2 h prior to the addition of arsenite. In experiments employing PD98059, SB202190, aspirin, piroxicam, and NS-398, vehicle concentrations were maintained below 0.5%.
DNA synthesis. NHEK were seeded into 24-well tissue culture plates (12,000 cells/well) in KBM-2 and grown to 60 -80% confluence. Medium was replaced with fresh KBM-2 containing 0, 1, 2.5, or 5 M arsenite. Cells were labeled for 2 h with 1 Ci/ml [ 3 H]-thymidine (Amersham Pharmacia, Piscataway, NJ) at 46 h of arsenite exposure and then washed several times with ice-cold Hank's balanced salt solution (HBSS). Following several washes with 10% trichloroacetic acid (Mallinckrodt, Phillipsburg, NJ), radioactivity was eluted using 0.3 N NaOH and [
3 H]-thymidine incorporation into DNA was quantified (counts per minute, CPM, are expressed as percentages of control) by scintillation counting. In experiments employing nonsteroidal anti-inflammatory drugs (NSAIDs), medium was replaced with fresh KBM-2 containing 2.5 M arsenite in combination with 1000 M aspirin, 10 M NS-398, and 10 M piroxicam. NSAID concentrations were based on therapeutic doses as previously reported (Dromgoole et al., 1983; Futaki et al., 1993; Hobbs, 1983) and on cytotoxicity data for NHEK. NHEK cytotoxicity was quantified using the neutral red cytotoxicity assay and was not increased following coexposure to 2.5 M arsenite plus aspirin, NS-398, or piroxicam at 1000 M, 10 M, and 10 M, respectively (unpublished data).
Northern blotting. NHEK were seeded into 150-mm tissue culture dishes (300,000 cells/dish) in KBM-2 and grown to 60 -80% confluence, at which time the medium was replaced with KBM-2 . Following a 1 to 2 h acclimation at 37°C, arsenite was added to a final concentration of 0, 1, 2.5, or 5 M (in duplicate). After arsenite treatment, NHEK were washed with ice-cold HBSS, cell pellets were obtained from duplicate plates, and RNA was isolated using the RNeasy mini-prep system (Qiagen, Valencia, CA). Next, 20 g aliquots of total RNA were fractionated by formaldehyde-agarose gel electrophoresis. Following transfer to nylon membranes and UV cross-linking, membrane-bound RNA was hybridized using QuikHyb solution (Stratagene, La Jolla, CA) to a 32 P-labeled human probe for human cox-2 prepared using random primers methodology (Invitrogen). Membranes were exposed to phosphoimager screens and gene expression was visualized using a Molecular Dynamics phosphoimager and Image Quant software (Amersham Pharmacia).
Western blotting. NHEK were seeded into 100-mm tissue culture dishes (100,000 cells/dish) in KBM-2 and grown to 60 -80% confluence, at which time the medium was replaced with KBM-2 . After a 1 to 2 h acclimation at 37°C, arsenite was added to the culture medium. Following arsenite treatment, cells were disrupted in ice-cold lysis buffer (10 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA [pH 8.0], 1% Triton X-100, 10% glycerol, 1 mM NaVO 4 , 1 mM NaF, 5 mM DTT, 10 g/ml leupeptin, 20 g/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride) prior to protein quantification. Lysates were combined with NuPage LDS buffer (Invitrogen) under reducing conditions, and SDS-PAGE (15 g cellular protein) was performed on 4 -12% bis/tris gels (Invitrogen). Fractionated proteins were transferred onto Hybond (Amersham Pharmacia) nitrocellulose membranes and incubated with a goat polyclonal COX-2 antibody (Caymen Chemicals, Ann Arbor, MI). For MAPK analysis, membranes were incubated with polyclonal antibodies for either anti-phospho/active p42/44, p38, MEK-1, -2, nonphosphorylated p38 (Cell Signaling/New England Biolabs, Inc., Beverly, MA), or nonphosphorylated p42/44 MAPK (Upstate Biotechnologies, Waltham, MA). A rabbit secondary antibody to IgG conjugated to horseradish peroxidase was used for chemiluminescence detection and proteins were visualized using the ECL detection system (Amersham Pharmacia), according to the manufacturer's instructions. Protein expression was quantified using a Molecular Dynamics laser densitometer and Image Quant software (Amersham Pharmacia). PGE 2 measurements. NHEK were seeded into 12-well tissue culture dishes (15,000 cells/dish) in KBM-2 and grown to 60 -80% confluence, at which time the medium was replaced with KBM-2 containing 0, 1, 2.5, or 5 M arsenite. Following treatment, culture medium was collected, centrifuged at 12,000 ϫ g for 5 min to remove cell debris, and frozen at -80°C prior to analysis. PGE 2 in culture medium was measured by enzyme immunoassay (Oxford Biomedical Research Inc., Oxford, MI), according to the manufacturer's instructions. Quantification was performed using a Molecular Devices (Sunnyvale, CA) kinetic microplate reader and SoftMax Pro software.
Statistical analysis. When appropriate, analysis of variance (ANOVA) was performed. Following ANOVA, significant differences were determined by application of the Tukey-Kramer Multiple Comparisons Test or the Students t-test (p Յ 0.05). All experiments were performed a minimum of three times unless otherwise indicated.
RESULTS
COX-2 contributes to proliferation in keratinocytes (RysSikora et al., 2000) . Previous studies from our laboratory indicated that arsenite elevated cox-2 mRNA in NHEK at concentrations relevant to those seen in arsenic-exposed populations (Hamadeh et al., 2002) . At 4, 8, and 24 h of exposure, arsenite elevated cox-2 message (ϳ4.1 kb) in NHEK, as determined by northern blotting (Fig. 1) . COX-2 expression was evaluated by western analysis using an antihuman COX-2 antibody, and, as shown in Figure 2 , COX-2 protein (ϳ70 kDa) was increased at 2.5 and 5 M arsenite (at 8 and 12 but not at 4 h of exposure). The increase in cox-2 expression at 4 h is consistent with transcription occurring prior to translation. Because a significant change in COX-2 protein was not observed at arsenite concentrations Յ 1 M, subsequent experiments were performed using concentrations between 1 and 5 M.
COX-2 catalyzes the synthesis and release of prostaglandins that are proposed to be involved in arsenic-mediated cardiovascular disease (Bunderson et al., 2002) and possibly cancer. Figure 3 shows that arsenite stimulated a significant increase in PGE 2 at the 2 and 5 M concentrations; an increase in baseline http://toxsci.oxfordjournals.org/ PGE 2 (0 M arsenite) occurred over a period of 48 h, similar to that reported previously (Maloney et al., 1998) . The finding that low levels of arsenite (e.g., 0.005-1 M) failed to stimulate PGE 2 secretion, where changes in cox-2 were seen, may be due in part to COX-independent mechanisms (e.g., increased arachidonic acid release) involved in prostaglandin synthesis or post-translational modifications of COX-2 that are important in its enzymatic activity (Hoozemans et al., 2002; Shimokawa et al., 1990) .
To determine if arsenite influences MAPK signaling in NHEK, p42/44 and p38 MAPK activation was examined using phosphorylation-specific MAPK antibodies. Concentrations of 2.5 (Fig. 4A ) and 5 M (unpublished data) arsenite stimulated a transient (5-30 min) and delayed (2, 3, and 4 h) increase in p42/44 MAPK phosphorylation. EGF, a growth factor that activates MAPKs in numerous cell types including keratinocytes (Medema et al., 1994) , stimulated p42/44 phosphorylation in a sustained manner (Fig. 4B) . Figures 4A and 4B show that the level of nonphosphorylated p42/44 following arsenite or EGF stimulation remained the same, indicating that changes in p42/44 phosphorylation were not due to alterations in steady-state protein level. Immune complex kinase assays also revealed that arsenite and EGF increased p42/44 MAP kinase activity similar to phosphorylation (unpublished data). The kinetics of MEK-1/-2 phosphorylation were similar to that of FIG. 3. Sodium arsenite stimulates PGE 2 secretion in NHEK. Cells were cultured as described in the materials and methods and an ELISA was performed on conditioned medium from medium-and arsenite-treated groups. Each point represents the mean (pg/ml) of three biological replicates; error bars denote SD and asterisks (*) indicate a significant difference (p Յ 0.05) from time-matched controls (no arsenite).
FIG. 4. Phosphorylation of p42/44
MAPK and MEK1, 2 in response to sodium arsenite treatment. NHEK treated with 2.5 M arsenite or 10 ng/ml EGF for 0 min to 4 h were analyzed by SDS-PAGE (15 g protein) and immunoblotting for (A) arsenite: anti-phospho/active p42/44, nonphosphorylated p42/44, or MEK1, 2, and (B) EGF: anti-phospho/ active p42/44 or nonphosphorylated p42/ 44. Similar results were obtained in two or more independent experiments. p42/44, confirming that arsenite exposure results in the activation of the kinase upstream of p42/44 MAPKs (Fig. 4A) , although the mechanism is still unknown. In contrast, arsenite did not stimulate phosphorylation of the stress kinase p38 at a concentration of 2.5 M (Fig. 5A) , whereas EGF induced p38 phosphorylation within 5 min of exposure (Fig. 5B) . These data indicate that arsenite stimulates rapid phosphorylation of p42/44 MAPKs, but not p38 MAPK, in NHEK.
MAPKs regulate COX-2 expression and function; therefore, the effect of arsenite on COX-2 expression in the presence of the MEK inhibitor PD98059 (20 M) or the p38 MAPK inhibitor SB202190 (5 M) was examined. PD98059 and SB202190 are specific inhibitors of the 42/44-and 38-kDa MAPK pathways, respectively. Both inhibitors, independently, decreased the elevation in COX-2 protein (ϳ70 kDa) at 12 h of arsenite exposure (Fig. 6) , an effect consistent with the roles of p42/44 and p38 in COX-2 regulation (Dean et al., 1999; Mifflin et al., 2002) . Similar effects occurred with the MEK inhibitor U0126 and p38 inhibitor SB203580 (unpublished data). To verify that the MAPK inhibitors were specific for their intended pathways, the effects of SB202190 and PD98059 on p42/44 and p38 phosphorylation in the presence of either 2.5 or 5 M arsenite were evaluated. PD98059 inhibited p42/44 phosphorylation, whereas SB202190 increased p38 phosphorylation (Fig. 7) . SB202190 did not affect p42/44 phosphorylation, and the MEK-1 inhibitor PD98059 did not stimulate p38 phosphorylation. These data indicate that PD98059 had a specific effect on the p42/44 and SB202190 on the p38 MAPK pathways. The stimulatory effect of SB202190 on p38 phosphorylation is thought to be due to inhibition of p38 MAPK activity via a loss of negative pathway regulation (Wang et al., 2000) .
Because arsenite can modulate proliferation in numerous cell types and abnormal proliferation is a key component of cancer, we studied whether a selective COX-2 inhibitor, N-(2-cyclohexyloxy-4-nitrophenyl) methanesulfonamide (NS-398), or general inhibitors of COX enzymes, 4-hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazine-3-carboxamid-1,1-dioxid (piroxicam) or acetylsalicylic acid (aspirin), could suppress arsenite-induced DNA synthesis. In NHEK, arsenite stimulated DNA synthesis in a dose-dependent manner after 48 (Fig. 8A ) and 72 h (Germolec et al., 1996; Vega et al., 2001 ) of exposure. As shown in Figure 8B , DNA synthesis stimulated by 2.5 M arsenite (at 48 h of exposure) was reduced by treatment with 1 mM aspirin, 10 M piroxicam, or 10 M NS-398. DNA synthesis stimulated by 5 M arsenite also was inhibited by piroxicam and NS-398 (unpublished data). These data indicate that NSAIDs reduce the ability of arsenite to stimulate 3 Hthymidine incorporation in NHEK.
DISCUSSION
Elevated expression and activity of the proinflammatory/ -carcinogenic enzyme COX-2 occurs in numerous carcinomas including those in skin, and studies in rodent and human tissues have indicated that overexpression of COX-2 contributes to FIG. 5. Phosphorylation of p38 MAPK in response to treatment with sodium arsenite or EGF. NHEK treated with 2.5 M arsenite (A) or 10 ng/ml EGF (B) for 0 min to 4 h were analyzed by SDS-PAGE (15 g protein) and immunoblotting for the activated form of p38 MAPK and total p38 MAPK. The elevation in baseline (0 minutes/arsenite) p38 phosphorylation (compared to 0 minutes/EGF) is due to extended membrane/film exposure to detect potential changes in p38 phosphorylation.
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TROUBA AND GERMOLEC skin carcinogenesis (Buckman et al., 1998) . Because COX-2 participates in skin carcinogenesis and is induced by a variety of cytokines, growth factors, and tumor promoters, we investigated its modulation by arsenite using an in vitro culture system.
In NHEK, sodium arsenite stimulated time-and dose-dependent changes in COX-2 expression and PGE 2 secretion. Our data are consistent with a recent report by Tsai and coworkers showing the induction of COX-2 protein, mRNA, and PGE 2 secretion in human umbilical vascular endothelial cells (HUVECs) by arsenite (Tsai et al., 2002) . These authors demonstrated that modulation of COX-2 by arsenite was mediated through NF-B. In their study and another (Bunderson et al., 2002) , where arsenite-induced COX-2 expression was monitored in bovine aortic endothelial cells (BAECs), induction of COX-2 occurred at arsenite concentrations five to ten times higher than those used in our study. Our data indicate that arsenite modulates COX-2 expression in NHEK at concentrations (e.g., submicromolar to low micromolar) within the range of those found in contaminated drinking water and in the urine of humans consuming contaminated drinking water (Gebel, 2001) .
Similar to previous studies, our western analyses consistently showed the presence of a protein doublet that migrated at the appropriate COX-2 molecular weight (70 kDa; Habib et al., 1993) . Both bands in this doublet are thought to be COX-2; however, the higher molecular weight band is believed to represent the active form of this enzyme since COX-2 contains several tyrosine groups that are substrates for phosphorylation and are important in its enzymatic activity (Shimokawa et al., 1990) . Chemical modification of specific tyrosine residues by nitration also abolishes COX-2 enzyme catalytic activity (Deeb al., 2002) . In our experiments, the intensity of the lower molecular weight band diminished as the concentration of arsenite increased (8 and 12 h, Fig. 2) . Also, the MAPK inhibition experiments revealed that the lower molecular weight band was present to a greater extent following arsenite and inhibitor treatment (2.5 and 5 M, Fig. 6 ). These data are consistent with arsenite stimulating an increase in active/phosphorylated COX-2. Because human epidermis is a source of prostaglandins and PGE 2 regulates epidermal cell proliferation and cytokine secretion, it is noteworthy that changes in COX-2 expression and/or prostaglandin level may play a significant role in arsenite's tumor promoter-like activities.
The potential to modulate COX-2 in keratinocytes is strengthened by the fact that numerous MAPKs are activated by arsenic. In NHEK, arsenite stimulated p42/44 MAPK phosphorylation at concentrations similar to those reported previously (Barchowsky et al., 1999; Drobna et al., 2003) and at concentrations near those found in contaminated drinking water (Gebel, 2001) . LaRochelle and coworkers (1999) have reported p42/44 MAPK phosphorylation kinetics in response to keratinocyte growth factor (KGF/FGF-7) stimulation similar to those of this study; yet, the mechanism(s) and biological significance of biphasic (transient and delayed) kinase phosphorylation are not well understood. Interestingly, the kinetics of p42/44 MAPK phosphorylation stimulated by arsenite are different than those for EGF and suggest that low concentrations of arsenite initially target EGF-independent signaling in NHEK. EGF receptor-mediated signaling, nonetheless, is proposed to be a target of arsenic (Simeonova et al., 2002; Wu et al., 1999) . Many studies examining the effects on MAPK signaling have employed significantly higher concentrations of arsenic (Ն 100 M; Liu et al., 1996; Ludwig et al., 1998) . Although novel data have been derived from these studies, high-dose arsenic exposure is likely to modulate stress-, apoptotic-, or death-related events-events that may be more related to acute toxicity. This is in contrast to repeated, longterm, low-dose arsenic exposure, which would be predicted to produce chronic toxicity or carcinogenesis.
Our data suggest that both p42/44 and p38 MAPK signaling contribute to the regulation of COX-2 by arsenite, as treatment with PD98059 or SB202190 prevented maximal COX-2 induction. Inhibition of MEK-1, -2, or p38 did not completely abrogate the increases in COX-2, indicating that additional events contribute to COX-2 regulation by arsenite. Chen and coworkers reported that p42/44 MAPKs do not play a role in the stimulation of cox-2 expression by UVB radiation in immortalized human keratinocytes, whereas activation of p38 is required for cox-2 induction (Chen et al., 2001) . These data, along with ours, indicate that the mechanisms involved in skin carcinogenesis are unique to the environmental insult and/or cell type. The finding that p38 phosphorylation is not stimulated transiently by arsenite yet treatment with SB202190 leads to a reduction in arsenite-induced COX-2 expression is difficult to resolve. One possibility is that arsenite stimulates p38 phosphorylation at a later time point(s) than those examined or, alternatively, that it induces/represses the action of a secondary mediator(s) that modulates p38 activation in a delayed manner.
COX-2 induction and MAPK activation occurred at concentrations of arsenite that also stimulated DNA synthesis. NSAIDs that inhibit COX enzymes are promising chemopreventative agents for human cancers including skin cancer (Marks and Furstenberger, 2000) , and it has been suggested that the inhibitory effect of some NSAIDs on carcinogenesis occurs during the tumor promotion step (i.e., during proliferation; Castano et al., 1997) . Our findings indicate that aspirin, piroxicam, or NS-398 partially suppressed the stimulatory effect of arsenite on DNA synthesis and implicated COX enzymes in the modulation of keratinocyte proliferation by arsenite. Specific NSAIDs not only inhibit cyclooxygenases but also modulate mitogenic events including MAPK (e.g., ERK and JNK) and transcription factor (e.g., AP-1) activation (Huang et al., 1997; Liu et al., 2003) . In some cases, MAPK   FIG. 7 . Effect of MAPK inhibitors on p42/44 and p38 MAPK phosphorylation. NHEKs were exposed to arsenite (2.5 or 5 M) and PD98059 (20 M) or SB202190 (5 M) as described in the materials and methods. Western blots using anti-phospho/active p42/44 or p38 antibodies showing that SB202190 has no effect on p42/44 phosphorylation or PD98059 on p38 phosphorylation. Similar results were obtained in two independent experiments.
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TROUBA AND GERMOLEC at Pennsylvania State University on February 21, 2013 http://toxsci.oxfordjournals.org/ inhibition takes place when NSAID treatment precedes mitogenic stimulation (e.g., following UV irradiation) but not when treatment occurs concomitant with or following stimulation (Huang et al., 1997) . In our experiments, arsenite was added concurrently with aspirin, piroxicam, or NS-398, and the stimulation of p42/44 phosphorylation by arsenite was not inhibited by pretreatment with either 10 or 30 M NS-398 (unpublished data). The latter suggests that inhibition of early MAPK/transcription factor activation is not critical in arsenite-induced DNA synthesis attenuation following NSAID treatment.
In summary, the relationship between COX-2 induction and MAPK activation presents a possible mechanism(s) involved in arsenic-induced dermatotoxicity, preneoplastic events, and skin cancer, and one that may be of particular toxicological relevance. Altered COX-2 expression, mediated partially by MAPKs, would be predicted to contribute to skin carcinogenesis by influencing inflammation, apoptosis, proliferation, differentiation, metabolism, and immunity. 
